Contribute Try STAT+ Today

Responding to rising drug prices and persistent shortages, a dozen large hospital systems have joined Civica Rx, a fledgling not-for-profit generic manufacturer that was created last year by seven other big hospital groups with $100 million in backing from philanthropic organizations. All totaled, about 750 U.S. hospitals have joined the effort.

The move is the latest sign of growing frustration among hospitals over pricing practices and quality-control issues that have hampered budgets and patient care. “Drug shortages have become a national crisis where patient treatments and surgeries are canceled, delayed or suboptimal,” said Martin VanTrieste, a former Amgen (AMGN) executive, who was hired to run the effort, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.